“牛散”杨兴礼再被监管警示

Group 1 - The core issue involves shareholders Yang Xingli and his associates failing to timely notify the company of a 1% increase in their combined shareholding, violating regulations [1][2] - The combined shareholding of Yang Xingli, Yang Mingtai, and Yang Yuetong increased from 5.65% to 6.35% after buying 1.1795 million shares and selling 887,000 shares between February 24, 2025, and July 7, 2025 [1][2] - The stock price of Dayang Bio fluctuated significantly during the trading period, with a minimum price of 17.01 yuan per share and a maximum of 31.9 yuan per share, resulting in a price fluctuation of 69% [2] Group 2 - Dayang Bio's main business includes the production and sale of inorganic salts and veterinary raw materials [3] - The company expects a net profit of 45 million to 55 million yuan for the first half of the year, representing a year-on-year growth of 43.15% to 74.96%, driven by increased production, sales, and prices of potassium carbonate and veterinary raw materials [3] - The Zhejiang Securities Regulatory Bureau has mandated that the shareholders improve their understanding of relevant laws and regulations to prevent future violations [3]